MYOKARDİYAL NİTRİK OKSİT VE KARDİYAK PERFORMANS ÜZERİNE DEFEROKSAMİNLİ KAN KARDİYOPLEJİSİNİN ETKİLERİ

Year 2000, Volume: 1 Issue: 1, 21 - 26, 01.04.2000

Tamer Bakalım Berent Dişçigil M. İsmail Badak Mehmet Boğa Uğur Gürcün Fatih İslamoğlu Tahir Yağdı Suat Buket İsa Durmaz Önol Bilkay

Abstract

-

Keywords

Deferoksamin, Nitrik oksit, Myokard korunması

Effects of Blood Cardioplegia With Deferroxamine on Myocardial Nitric Oxide Production and Myocardial Performance

Abstract

Objective: The effects of deferroxamine addition to routine blood cardioplegia on left ventricular function, myocardial nitric oxide (NO) production and hemodynamics were assessed. Methods: Twenty patients who underwent coronary artery bypass grafting (CABG) electively were studied in two groups, 10 in each. Ten patients in whom routine blood cardioplegia was used served as controls. In the other 10 patients (study group), blood cardioplegia with deferroxamine was used. Mean age was 61.30+2.12 in the control group, and 53.20±3.21 in the study group. The number of distal anastomoses, X-clamp and cardiopul-monary bypass (CPB) times were similar in two groups. Cardioplegia was delivered antegradely in both groups. Blood samples were taken from the coronary sinus. Hemodynamic measurements were done before and follow-ing CPB. Results: In the study group, myocardial NO levels were found to be higher at all sampling times, however, the difference was statistically significant only following CPB. Creatine kinase MB isoenzyme levels reflecting the degree of myocardial injury were measured lower in the study group postoperatively(p< 0.05). There was no difference in hemodynamics between the two groups. Conclusions: These findings demonstrate that the addition of deferroxamine to blood cardioplegic solution maintains higher myocardial NO levels indicating better endothelial function and causes less myocardial injury. Blood cardioplegia with deferroxamine is a valuable alternative method of myocardial protection during aortic cross clamping in cardiac surgery.

Keywords

Deferroxamine, nitric oxide, myocardial protection

References

• 1. Diþçigil B, Pearson PJ, Chua YL, Evora PRB, Seccombe JF, Schaff HV. Novel technique to bioassay endocardiumderived nitric oxide from the beating heart. Ann Thorac Surg 1995; 59: 1182-6.
• 2. Braunwald E. Hemostasis, thrombosis, fibrinolysis and cardiovascular disease. In: Valantin F, Verstraete M (eds). Heart Disease, A Textbook of Cardiovascular Medicine, 3rd ed. Pannsylvania: WB Saunders Company, 1997: 60.
• 3. Fantone JC, Ward PA. Role of oxyigen-derived free radicals and metabolites in leucocyte dependent inflam￾matory reactions. Am J Pathol 1982; 107: 395-9.
• 4. Ko W, Hawes AS, Lazenby WD, et al. Myokardial repefusion injury. J Thorac Cardiovasc Surg 1991; 1020: 297-308.
• 5. Menasche P, Piwnica A. Free radicals and myocardial protection: a surgical view point. Ann Thorac Surg 1989; 47: 939-45.
• 6. Ricardo F, Susana L, Jose M, Domingo S. Assessment of myokardial oxidative stress in patients after myocardia revascularization. Am Heart J 1988; 15: 307-12.
• 7. Rau EE, Shine KI, Gervais A, et al. Enhanced mechanical recovery of anoxic and ischemic myocardium by aminoacid perfusion. Am J Physiol 1979; 236: 873-9.
• 8. Rosenkranz ER, Okamoto F, Buckberg GD, et al. Safety of prolonged aortic clamping with blood cardioplegia. II. Glutamate enrichment in energy-depleted hearts. J Thorac Cardiovasc Surg 1984; 88: 402-10.
• 9. Tsao PS, Aoki N, Lefer DJ et al. Time course of endothelial dysfunction and myocardial injury during myocardial ischemia and reperfusion in the cat. Circulation 1990; 82: 1402-12.
• 10. Dignan RJ, Dyke CM, Abd.-Elfattah AS, et al. Coronary artery endotheliel cell and smooth muscle dysfunction after myocardial ischemia. Ann Thorac Surg 1992; 53: 311-7.
• 11. Nakanishi K, Zhao Z-Q, Vinten Johansen J, Lewis JC, Mc Gee DS, Hammon JW. Coronary artery endothelial dysfunction after ischemia, blood cardioplegia and reperfusion. Ann Thorac Surg 1994; 58: 191-9.
• 12. Sato H, Zhao Z-Q, Jordan JE, Riley RD, et al. Basal NO expresses endogenous cardioprtection during reperfusion by inhibition of neutrophil-mediated damage after surgical revascularization. J Thorac Cardiovasc Surg 1997; 113: 399-409.
• 13. Mizuno A, Baretti R, Buckberg GD,Young HH,Vinten Johasen J, Ma XL, IgnarroLJ. Endothelial stunning and myocyte recovery after reperfusýon of jeopardized muscle.J Thorac Surg 1997; 113: 379-89.
• 14. Drassos G, Lazou A, Panagapoulos P, Westeby S. Deferoxamine Cardiolpegia reduces superoxide radical production in human myocardium. Ann Thorac Surg 1995; 59: 169-72.
• 15. Furlong B, Henderson AH, Lewis MJ, Smith JA. Endotheilum derived relaxing factor inhibits in vivo platelet agregation. Br J Pharmacol 1987; 90: 687-692.
• 16. Kawata H, Sawatari K, Mayer JEJ. Evidence for the role of neutrophils in reperfusion injury after cold cardioplegic ischemia in neonatal lambs. J Thorac Cardiovasc Surg 1991; 103: 908-18.
• 17. Mc Call T, White BJR, BoughtonSmith NK, Moncada S. Inhibition of FMLP-induced aggregation of rabbit neutrophils by nitric oxide (Abstract) Br J Pharmacol 1988; 95: 517.
• 18. Mizuno A, Baretti R, Buckberg GD, et al. Endothelial stunning and myocyte recovery after reperfusýon of jeopardized muscle. J Thorac Surg 1997; 113: 379-89.
• 19. Rubyani GM,Ho EH, Cantor EH, Lumma WC, Parker￾Botelho LH. Cytoprotective function of nitric oxide interactivation of superoxide radicals produced by human leukocytes. Biochem Biophys Res Commun 1991; 181:1397-7.